BioCentury
ARTICLE | Company News

Roche acquires Versant's MS play Inception 5, VC launches another

April 4, 2018 12:41 PM UTC

Roche (SIX:ROG; OTCQX:RHHBY) is exercising its option to acquire Versant Venture’s remyelination play Inception 5 Inc. Concurrently, the VC is doubling down on regenerative therapies for neurology through the launch of successor company Pipeline Therapeutics Inc., which has ambitions in and beyond remyelination.

Inception 5 was spun out of Versant’s small molecule discovery engine Inception Sciences Inc. (San Diego, Calif.) in a 2014 build-to-buy deal with Roche. Versant provided equity financing while Roche gave funds for research. The financial terms of the deal remain undisclosed (see BioCentury, June 30, 2014)...